In patients with CAD and CKD, the primary outcome of MACEs occurred in 119 (8.47%) patients with P2Y12 inhibitor monotherapy and 139 (9.65%) patients with DAPT. The gene discussed is P2RY12; the disease is chronic kidney disease.